186 related articles for article (PubMed ID: 31069158)
1. Clinical significance of CD8
Tang W; Pan X; Han D; Rong D; Zhang M; Yang L; Ying J; Guan H; Chen Z; Wang X
Oncoimmunology; 2019; 8(6):e1593807. PubMed ID: 31069158
[TBL] [Abstract][Full Text] [Related]
2. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
[TBL] [Abstract][Full Text] [Related]
3. PD-1 and TIGIT coexpressing CD8 + CD103 + tissue-resident memory cells in endometrial cancer as potential targets for immunotherapy.
Jiang F; Mao M; Jiang S; Jiao Y; Cao D; Xiang Y
Int Immunopharmacol; 2024 Jan; 127():111381. PubMed ID: 38150880
[TBL] [Abstract][Full Text] [Related]
4. Increased frequency of TIGIT
Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
[TBL] [Abstract][Full Text] [Related]
5. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
6. Expression of the immune checkpoint receptor TIGIT in seminoma.
Hinsch A; Blessin NC; Simon R; Kluth M; Fischer K; Hube-Magg C; Li W; Makrypidi-Fraune G; Wellge B; Mandelkow T; Debatin NF; Höflmayer D; Lennartz M; Sauter G; Izbicki JR; Minner S; Büscheck F; Uhlig R; Dum D; Krech T; Luebke AM; Wittmer C; Jacobsen F; Burandt E; Steurer S; Wilczak W
Oncol Lett; 2019 Aug; 18(2):1497-1502. PubMed ID: 31423216
[TBL] [Abstract][Full Text] [Related]
7. [The number of TIGIT
Xie A; Li J; Fang C; Shi F; Xing J; Mo F; Xie H; Huang J; Wei H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Aug; 39(8):673-679. PubMed ID: 37515332
[TBL] [Abstract][Full Text] [Related]
8. Peritumoral TIGIT
Liu H; Wu J; Xu X; Wang H; Zhang C; Yin S; He Y
Int Immunopharmacol; 2022 Jul; 108():108735. PubMed ID: 35405596
[TBL] [Abstract][Full Text] [Related]
9. Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
Zhang P; Liu X; Gu Z; Jiang Z; Zhao S; Song Y; Yu J
Biomark Res; 2024 Jan; 12(1):7. PubMed ID: 38229100
[TBL] [Abstract][Full Text] [Related]
10. CD226 identifies functional CD8
Huang H; Huang Z; Ge J; Yang J; Chen J; Xu B; Wu S; Zheng X; Chen L; Zhang X; Jiang J
Front Immunol; 2023; 14():1150803. PubMed ID: 37056782
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral TIGIT
Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study.
Ren DF; Zheng FC; Zhao JH; Shen GS; Ahmad R; Zhang SS; Zhang Y; Kan J; Dong L; Wang ZY; Zhao FX; Zhao JD
World J Clin Cases; 2018 Sep; 6(10):373-383. PubMed ID: 30283800
[TBL] [Abstract][Full Text] [Related]
13. Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8
Shaw G; Cavalcante L; Giles FJ; Taylor A
J Hematol Oncol; 2022 Sep; 15(1):134. PubMed ID: 36104795
[TBL] [Abstract][Full Text] [Related]
14. CD155T/TIGIT Signaling Regulates CD8
He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
[TBL] [Abstract][Full Text] [Related]
15. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
Grapin M; Richard C; Limagne E; Boidot R; Morgand V; Bertaut A; Derangere V; Laurent PA; Thibaudin M; Fumet JD; Crehange G; Ghiringhelli F; Mirjolet C
J Immunother Cancer; 2019 Jun; 7(1):160. PubMed ID: 31238970
[TBL] [Abstract][Full Text] [Related]
16. Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.
Shirasuna K; Koelsch G; Seidel-Dugan C; Salmeron A; Steiner P; Winston WM; Brodkin HR; Nirschl CJ; Abbott S; Kinugasa F; Sugahara S; Ohori M; Takeuchi M; Hicklin DJ; Yoshida T
Cancer Treat Res Commun; 2021; 28():100433. PubMed ID: 34273876
[TBL] [Abstract][Full Text] [Related]
17. Blockade of T-cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV-related HCC in mice.
Wu Y; Hao X; Wei H; Sun R; Chen Y; Tian Z
Hepatology; 2023 Mar; 77(3):965-981. PubMed ID: 35938354
[TBL] [Abstract][Full Text] [Related]
18. TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer.
Heiduk M; Klimova A; Reiche C; Digomann D; Beer C; Aust DE; Distler M; Weitz J; Seifert AM; Seifert L
Clin Cancer Res; 2023 Jul; 29(14):2638-2650. PubMed ID: 37140899
[TBL] [Abstract][Full Text] [Related]
19. Co-inhibition of TIGIT, PD1, and Tim3 reverses dysfunction of Wilms tumor protein-1 (WT1)-specific CD8+ T lymphocytes after dendritic cell vaccination in gastric cancer.
Lu X; Liu J; Cui P; Liu T; Piao C; Xu X; Zhang Q; Xiao M; Liu X; Wang Y; Yang L
Am J Cancer Res; 2018; 8(8):1564-1575. PubMed ID: 30210924
[TBL] [Abstract][Full Text] [Related]
20. T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients.
Kong Y; Zhu L; Schell TD; Zhang J; Claxton DF; Ehmann WC; Rybka WB; George MR; Zeng H; Zheng H
Clin Cancer Res; 2016 Jun; 22(12):3057-66. PubMed ID: 26763253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]